Back to search results

Haloperidol for Cannabinoid Hyperemesis Syndrome in the Emergency Department

This study is looking at whether an outpatient prescription for haloperidol can help people with Cannabinoid Hyperemesis Syndrome (CHS) avoid returning to the emergency department. CHS is a condition causing severe nausea, vomiting, and stomach pain in people who use cannabis. If you are diagnosed with CHS in the emergency department and are safe to go home, you might receive a prescription for haloperidol to use as needed. The main goal is to see if having this medication at home prevents you from needing to come back to the emergency department for your symptoms. We are looking for about 100 participants aged 18 and older who meet specific diagnostic criteria for CHS.

Study design
This is an interventional study planning to enroll 100 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 1 month to measure the rate of return to the emergency department.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07726069

Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

Not Yet Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
University of Illinois at Chicago
~100 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:Haloperidol

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of return to the emergency department
Measured over 1 month

Conditions

Cannabinoid Hyperemesis Syndrome

Explore related trials

Cannabinoid Hyperemesis Syndrome

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Wesley Eilbert, MD · PRINCIPAL_INVESTIGATOR · University of Illinois Health

Who to contact

Mason A Bartman, MD
[email protected]
8178972205
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients who meet ROME-4 diagnostic criteria for cannabinoid hyperemesis syndrome

What this trial measures

  • Rate of return to the emergency department1 month

    We plan to measure the percentage of people who return to the emergency department for recurrence of symptoms attributable to cannabinoid hyperemesis syndrome